{"company":{"id":3785505,"name":"CONNECTA Therapeutics","domain":"connectatherapeutics.com","url":"https://alion.io/company/connectatherapeutics"},"section":"news","answer":"CONNECTA Therapeutics: 7 headlines on record, 1 headline in the last 90 days.","figures":[{"label":"Headlines","value":"7"},{"label":"In 90 days","value":"1"},{"label":"Milestones","value":"0"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":7}],"news":[{"date":"2026-09-10","kind":"Blog","title":"CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program","url":"https://connectatherapeutics.com/news/connecta-therapeutics-announces-financing-to-advance-clinical-development-of-fragile-x-syndrome-program/"},{"date":"2026-07-02","kind":"Blog","title":"CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026","url":"https://connectatherapeutics.com/news/connecta-therapeutics-and-centre-for-genomic-regulation-to-present-first-in-class-program-cth120-for-fragile-x-syndrome-at-fens-forum-2026/"},{"date":"2026-06-10","kind":"Blog","title":"CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome","url":"https://connectatherapeutics.com/news/connecta-therapeutics-initiates-phase-iia-clinical-trial-of-cth120-a-first-in-class-neuroplasticity-modulator-in-fragile-x-syndrome/"},{"date":"2025-09-09","kind":"Blog","title":"CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support","url":"https://connectatherapeutics.com/news/connecta-therapeutics-to-advance-cth120-into-phase-ii-pediatric-development-for-fragile-x-syndrome-with-eic-accelerator-support/"},{"date":"2025-03-04","kind":"Blog","title":"CONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120","url":"https://connectatherapeutics.com/news/connecta-therapeutics-announces-positive-results-from-phase-i-study-of-neurodevelopmental-disorders-drug-candidate-cth120/"},{"date":"2025-02-18","kind":"Blog","title":"CONNECTA Therapeutics selected for funding under the EIC Accelerator","url":"https://connectatherapeutics.com/news/connecta-therapeutics-selected-for-funding-under-the-eic-accelerator/"},{"date":"2024-02-12","kind":"Blog","title":"CONNECTA Therapeutics, CRG, Hospital del Mar Research Institute and I3PT receive €2.7 million from the Spanish Ministry of Science and Innovation to begin Phase IIa trials for CTH120 in Fragile X syndrome","url":"https://connectatherapeutics.com/news/connecta-therapeutics-crg-hospital-del-mar-research-institute-and-i3pt-receive-e2-7-million-from-the-spanish-ministry-of-science-and-innovation-to-begin-phase-iia-trials-for-cth120-in-fragile-x-synd/"}],"as_of":"2026-11-17","cite":"CONNECTA Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/connectatherapeutics/news","html_url":"https://alion.io/company/connectatherapeutics/news","json_url":"https://alion.io/company/connectatherapeutics/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T13:19:09Z"}}